ObjectiveTo determine postoperative pain of the robotic technique for the patients with lobectomy. MethodsWe retrospectively analyzed the clinical data of 120 patients with lobectomy between October 2014 and May 2015 in our hospital. The patients are divided into two groups:a robotic group, including 40 patients with 16 males and 24 females at age of 59.7±7.2 years, undergoing robotic lobectomy, and a video-assisted thoraciscopic surgery (VATS) lobectomy group (a VATS group) including 80 patients with 29 males and 51 females at age of 61.2±8.9 years, undergoing VATS lobectomy. We used the numerical rating scale (NRS) and verbal rating scale (VRS) to assess the pain level on the first day, the 7th day and the 30th day after the surgery. The pain level of the two groups was compared. ResultsThe patients in the two groups both felt pain. There were no statistical differences in the scores of VRS and NRS on the first day, the 7th day and the 30th day after the surgery between the two group (P>0.05). The pain score of the patients in the two groups decreased with no statistical difference from the first day to the 30th day after the surgery (P>0.05). ConclusionThe patients with robotic lobectomy have similar pain level after surgery compared with the patients with VATS lobectomy.
ObjectivesTo investigate the correlation of warfarin dose genetic and polymorphism of Han-patients after heart valve replacement, to forecast the anticoagulation therapy with warfarin reasonable dosage, and to realize individualized management of anticoagulation monitoring. MethodsWe selected 103 patients between January 1, 2011 and December 31, 2012 in West China Hospital of Sichuan University who were treated by oral warfarin after heart valve replacement with monitoring anticoagulation by international normalized ratio (INR) in Anticoagulation Therapy Database of Chinese Patients after Heart Valve Replacement. There were 32 males and 71 female at age of 21-85 (48.64± 11.66) years. All the patients' CYP2C9 and VKORC1 genetic polymorphisms were detected by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RELP) method and gene sequencing technology. Warfarin concentration in plasma was determined by high performance liquid chromatography (HPLC) method. The activity of coagulation factorⅡ, Ⅶ, Ⅸ, Ⅹwas determined by Sysmex CA7000 analyzer. ResultsThe multivariate linear regression analysis showed that age, body surface area, and coagulation factor activity had no significant effect on warfarin dosage. While the gene polymor-phisms of CYP2C9 and VKORC1, warfarin concentration, and age had significant contributions to the overall variability in warfarin dose with decisive coefficients at 1.2%, 26.5%, 43.4%, and 5.0% respectively. The final equation was:Y=1.963-0.986× (CYP2C9* 3) +0.893× (VKORC1-1639) +0.002× (warfarin concentration)-0.019× (age). ConclusionMultiple regression equation including gene polymorphisms of CYP2C9 and VKORC1, non-genetic factors of coagulation factor activity, warfarin concentration, age, and body surface area can predict reasonable dosage of warfarin for anticoagulation to achieve individualized management of anticoagulation monitoring and reduce the anticoagulation complications.